References
- Maarouf M, Clark AK, Lee DE, et al. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials. J Dermatolog Treat. 2018;29(5):441–449.
- Bechara FG, Podda M, Prens EP, et al. Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: the SHARPS randomized clinical trial. JAMA Surg. 2021;156(11):1001–1009.
- Marzano AV, Genovese G, Casazza G, et al. Evidence for a “window of opportunity” in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study. Br J Dermatol. 2021;184(1):133–140.
- Seivright JR, Thompson A, Hamzavi I, et al. Hidradenitis suppurativa specialty clinics in the USA. Skin Appendage Disord. 2021;7(5):359–362.
- Fernandez JM, Madsen S, Krase JM, et al. Classification and mitigation of negative injection experiences with biologic medications. Dermatologic Therapy [Internet]. 2020;33(2). DOI:10.1111/dth.13240.
- Caposiena Caro RD, Chiricozzi A, Sechi A, et al. Factors related to the onset and recurrence of flares in hidradenitis suppurativa patients treated with adalimumab. Ital J Dermatol Venerol. 2022;157:137–141.
- Caposiena Caro RD, Cannizzaro MV, Tartaglia C, et al. Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab. Clin Exp Dermatol. 2020;45(4):438–444.
- Bettoli V, Manfredini M, Calamo G, et al. Long-term adalimumab treatment of hidradenitis suppurativa: Results and practical insights from a real-life experience. Dermatol Ther. 2018;31(6):e12737.